Literature DB >> 16423428

Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression.

Erwin Lauwers1, Dirk Bequé, Koen Van Laere, Johan Nuyts, Guy Bormans, Luc Mortelmans, Cindy Casteels, Linda Vercammen, Olivier Bockstael, Bart Nuttin, Zeger Debyser, Veerle Baekelandt.   

Abstract

Parkinson's disease is a neurodegenerative disorder affecting the dopaminergic neurons in the substantia nigra. Aggregation of alpha-synuclein appears to play a central role in the pathogenesis. Novel animal models for neurodegeneration have been generated by lentiviral vector-mediated locoregional overexpression of disease-associated genes in the adult brain. We have used lentiviral vectors to overexpress a clinical mutant of alpha-synuclein, A30P, in the rat substantia nigra. This overexpression induced time-dependent cytoplasmic and neuritic accumulation of alpha-synuclein and neurodegeneration. A subgroup of the rats developed asymmetric rotational behavior after administration of amphetamine. In addition, these animals displayed reduced dopamine transporter binding visualized by 123I-FP-CIT microSPECT imaging. The behavioral and microSPECT data were validated by histological analysis. There was a strong correlation between the reduction of dopaminergic neurons in the substantia nigra and the reduction of dopamine transporter binding in the striatum. MicroSPECT imaging enables non-invasive imaging of the neurodegeneration allowing longitudinal follow-up in this new animal model for Parkinson's disease and the evaluation of neuroprotective drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423428     DOI: 10.1016/j.neurobiolaging.2005.12.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  12 in total

1.  Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2012-10-24       Impact factor: 6.167

Review 2.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

Review 3.  Parkinson's disease: experimental models and reality.

Authors:  Peizhou Jiang; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2017-11-18       Impact factor: 17.088

4.  Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6.

Authors:  Fabienne C Fiesel; Aaron Voigt; Stephanie S Weber; Chris Van den Haute; Andrea Waldenmaier; Karin Görner; Michael Walter; Marlene L Anderson; Jeannine V Kern; Tobias M Rasse; Thorsten Schmidt; Wolfdieter Springer; Roland Kirchner; Michael Bonin; Manuela Neumann; Veerle Baekelandt; Marianna Alunni-Fabbroni; Jörg B Schulz; Philipp J Kahle
Journal:  EMBO J       Date:  2009-11-12       Impact factor: 11.598

5.  Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson's disease discerned with microSPECT and quantitative MRI.

Authors:  Nadja Van Camp; Ruth Vreys; Koen Van Laere; Erwin Lauwers; Dirk Beque; Marleen Verhoye; Cindy Casteels; Alfons Verbruggen; Zeger Debyser; Luc Mortelmans; Jan Sijbers; Johan Nuyts; Veerle Baekelandt; Annemie Van der Linden
Journal:  MAGMA       Date:  2010-02-19       Impact factor: 2.310

Review 6.  The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models.

Authors:  Gabriella MacDougall; Logan Y Brown; Boris Kantor; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

7.  Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.

Authors:  Anthony C Vernon; William R Crum; Saga M Johansson; Michel Modo
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

8.  Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein.

Authors:  Eduard Bentea; Anke Van der Perren; Joeri Van Liefferinge; Anissa El Arfani; Giulia Albertini; Thomas Demuyser; Ellen Merckx; Yvette Michotte; Ilse Smolders; Veerle Baekelandt; Ann Massie
Journal:  Front Behav Neurosci       Date:  2015-03-31       Impact factor: 3.558

Review 9.  Parkinson's disease: animal models and dopaminergic cell vulnerability.

Authors:  Javier Blesa; Serge Przedborski
Journal:  Front Neuroanat       Date:  2014-12-15       Impact factor: 3.856

Review 10.  Adeno-Associated Virus Expression of α-Synuclein as a Tool to Model Parkinson's Disease: Current Understanding and Knowledge Gaps.

Authors:  Taylor E Huntington; Rahul Srinivasan
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.